Background: The human IgE response is associated with allergy and with host defence against parasitic worms. A response to Sm22.6, the dominant IgE antigen in adult Schistosoma mansoni worms, correlates with resistance to re-infection after treatment. Sm22.6 is one of a family of EF-hand containing parasite proteins with sequence similarity to dynein light chain (DLC) and with major non-parasite allergens. Here we compare human IgE and IgG responses to other family members, Sm20.8 and Sm21.7, as well as to SmDLC1, relating these to antigen structure and expression in parasite life stages. Methods: Recombinant antigens were used in ELISA to measure antibody isotype responses in 177 cases from an endemic area, before and 7 weeks after treatment. Parasite antigen expression was assessed by RT-PCR and Western blotting. Results: Levels of antibodies to Sm22.6 and Sm20.8 (but not to Sm21.7 or SmDLC1) showed posttreatment increases in all but young children. Many produced IgE to Sm22.6 and Sm20.8 (2 EF-hands), few to Sm21.7 (1 EF-hand) or SmDLC1 (no EF-hands). Sm21.7 was expressed in cercariae, adults and eggs, Sm22.6 and Sm20.8 were concentrated in the adult. Conclusions: These studies suggest that IgE antigens Sm22.6 and Sm20.8 are only released to boost antibodies when adult worms die, whilst Sm21.7 and SmDLC1 are released constantly from eggs dying in host tissue. IgE responses to these allergen-like molecules may be influenced by patterns of exposure and the number of EF-hand motifs.

Keywords:
Schistosoma mansoni, IgE response, human
1.
Yazdanbakhsh M, Kremsner PG, van Ree R: Allergy, parasites, and the hygiene hypothesis. Science 2002;296:490–494.
2.
King CH, Dickman K, Tisch DJ: Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005;365:1561–1569.
3.
Dunne DW, Butterworth AE, Fulford AJC, Kariuki HC, Langley JG, Ouma JH, Capron A, Pierce RJ, Sturrock RF: Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 1992;22:1483–1494.
4.
Rihet P, Demeure CE, Bourgois A, Prata A, Dessein A: Evidence for an association between human resistance to Schistosoma mansoni and high anti-larval IgE levels. Eur J Immunol 1991;21:2679–2686.
5.
Hagan P, Blumenthal UJ, Chaudri M, Greenwood BM, Hayes RJ, Hodgson J, Kelly C, Knight M, Simpson AJG, Smithers SR, Wilkins HA: Resistance to reinfection with Schistosoma haematobium in Gambian children: analysis of their immune responses. Trans R Soc Trop Med Hyg 1987;81:938–946.
6.
Capron M, Capron A: Immunoglobin E and effector cells in schistosomiasis. Science 1994;264:1876–1877.
7.
Dunne DW, Webster M, Smith P, et al: The isolation of a 22 kDa band after SDS-PAGE of Schistosoma mansoni adult worms and its use to demonstrate that IgE responses against the antigen(s) it contains are associated with human resistance to reinfection. Parasite Immunol 1997;19:79–89.
8.
Webster M, Fulford AJ, Braun G, et al: Human immunoglobulin E responses to a recombinant 22.6-kilodalton antigen from Schistosoma mansoni adult worms are associated with low intensities of reinfection after treatment. Infect Immun 1996;64:4042–4046.
9.
Santiago ML, Hafalla JC, Kurtis JD, Aligui GL, Wiest PM, Olveda RM, Olds GR, Dunne DW, Ramirez BL: Identification of the Schistosoma japonicum 22.6-kDa antigen as a major target of the human IgE response: similarity of IgE-binding epitopes to allergen peptides. Int Arch Allergy Immunol 1998;117:94–104.
10.
Fitzsimmons CM, Stewart TJ, Hoffmann KF, Grogan JL, Yazdanbakhsh M, Dunne DW: Human IgE response to the Schistosoma haematobium 22.6 kDa antigen. Parasite Immunol 2004;26:371–376.
11.
Stein LD, David JR: Cloning of a developmentally regulated tegument antigen of Schistosoma mansoni. Mol Biochem Parasitol 1986;20:253–264.
12.
Francis P, Bickle Q: Cloning of a 21.7-kDa vaccine-dominant antigen gene of Schistosoma mansoni reveals an EF hand-like motif. Mol Biochem Parasitol 1992;50:215–222.
13.
Hoffmann KF, Strand M: Molecular characterization of a 20.8-kDa Schistosoma mansoni antigen: sequence similarity to tegumental associated antigens and dynein light chains. J Biol Chem 1997;272:14509–14515.
14.
Waine GJ, Becker MM, Scott JC, Kalinna BH, Yang W, McManus DP: Purification of a recombinant Schistosoma japonicum antigen homologous to the 22-kDa membrane-associated antigen of S. mansoni, a putative vaccine candidate against schistosomiasis. Gene 1994;142:259–263.
15.
Hafalla JC, Alamares JG, Acosta LP, Dunne DW, Ramirez BL, Santiago ML: Molecular identification of a 21.7-kDa Schistosoma japonicum antigen as a target of the human IgE response. Mol Biochem Parasitol 1999;98:157–161.
16.
Mohamed MM, Shalaby KA, LoVerde PT, Karim AM: Characterization of Sm20.8, a member of a family of schistosome tegumental antigens. Mol Biochem Parasitol 1998;96:15–25.
17.
Ruiz de Eguino AD, Machin A, Casais R, et al: Cloning and expression in Escherichia coli of a Fasciola hepatica gene encoding a calcium-binding protein. Mol Biochem Parasitol 1999;101:13–21.
18.
Vichasri-Grams S, Subpipattana P, Sobhon P, Viyanant V, Grams R: An analysis of the calcium-binding protein 1 of Fasciola gigantica with a comparison to its homologs in the phylum Platyhelminthes. Mol Biochem Parasitol 2006;146:10–23.
19.
Li Y, Auliff A, Jones MK, Yi X, McManus DP: Immunogenicity and immunolocalization of the 22.6-kDa antigen of Schistosoma japonicum. Parasite Immunol 2000;22:415–424.
20.
Grogan JL, Kremsner PG, van Dam GJ, Metzger W, Mordmuller B, Deelder AM, Yazdanbakhsh M: Antischistosome IgG4 and IgE responses are affected differentially by chemotherapy in children versus adults. J Infect Dis 1996;173:1242–1247.
21.
Webster M, Fallon PG, Fulford AJ, Butterworth AE, Ouma JH, Kimani G, Dunne DW: Effect of praziquantel and oxamniquine treatment on human isotype responses to Schistosoma mansoni: elevated IgE to adult worm. Parasite Immunol 1997;19:333–335.
22.
Webster M, Roberts M, Fulford AJ, et al: Human IgE responses to rSm22·6 are associated with infection intensity rather than age per se, in a recently established focus of Schistomiasis mansoni. Trop Med Int Health 1998;3:318–326.
23.
Kabatereine NB, Kemijumbi J, Ouma JH, Kariuki HC, Richter J, Kadzo H, Madsen H, Butterworth AE, Ornbjerg N, Vennervald BJ: Epidemiology and morbidity of Schistosoma mansoni infection in a fishing community along Lake Albert in Uganda. Trans R Soc Trop Med Hyg 2004;98:711–718.
24.
Katz N, Chaves A, Pellegrino J: A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 1972;14:397–400.
25.
Hoffmann KF, Strand M: Molecular identification of a Schistosoma mansoni tegumental protein with similarity to cytoplasmic dynein light chains. J Biol Chem 1996;271:26117–26123.
26.
Naus CWA, Booth M, Jones FM, Kemijumbi J, Vennervald BJ, Kariuki CH, Ouma JH, Kabatereine NB, Dunne DW: The relationship between age, sex, egg-count and specific antibody responses against Schistosoma mansoni antigens in a Ugandan fishing community. Int J Trop Med Hyg 2003;8:561–568.
27.
Fitzsimmons CM, Schramm G, Jones FM, Chalmers IW, Hoffmann KF, Grevelding CG, Wuhrer M, Hokke CH, Haas H, Doenhoff MJ, Dunne DW: Molecular characterization of omega-1: a hepatotoxic ribonuclease from Schistosoma mansoni eggs. Mol Biochem Parasitol 2005;144:123–127.
28.
Kabatereine NB, Vennervald BJ, Ouma JH, Kemijumbi J, Butterworth AE, Dunne DW, Fulford AJ: Adult resistance to schistosomiasis mansoni: age-dependence of reinfection remains constant in communities with diverse exposure patterns. Parasitology 1999;118:101–105.
29.
Pearce EJ, Sher A: Mechanisms of immune evasion in schistosomiasis. Contrib Microbiol Immunol 1987;8:219–232.
30.
Woolhouse MEJ, Hagan P: Seeking the ghosts of worms past. Nat Med 1999;5:1225–1227.
31.
Fulford AJ, Butterworth AE, Ouma JH, Sturrock RF: A statistical approach to schistosome population dynamics and estimation of the life-span of Schistosoma mansoni in man. Parasitology 1995;110:307–316.
32.
Feldman GM, Dannenberg AM Jr, Seed JL: Physiologic oxygen tensions limit oxidant-mediated killing of schistosome eggs by inflammatory cells and isolated granulomas. J Leukoc Biol 1990;47:344–354.
33.
Jeffs SA, Hagan P, Allen R, Correa-Oliveira R, Smithers SR, Simpson AJ: Molecular cloning and characterisation of the 22-kilodalton adult Schistosomamansoni antigen recognised by antibodies from mice protectively vaccinated with isolated tegumental surface membranes. Mol Biochem Parasitol 1991;46:159–167.
34.
Geha, RS, Jabara HH, Brodeur SR: The regulation of immunoglobulin E class-switch recombination. Nat Rev Immunol 2003;3:721–732.
35.
Till SJ, Francis JN, Nouri-Aria K, Durham SR: Mechanisms of immunotherapy. J Allergy Clin Immunol 2004;113:1025–1034.
36.
Bellinghausen I, Knop J, Saloga J: The role of interleukin 10 in the regulation of allergic immune responses. Int Arch Allergy Immunol 2001;126:97–101.
37.
Jutel M, Akdis M, Blaser K, Akdis CA: Are regulatory T cells the target of venom immunotherapy? Curr Opin Allergy Clin Immunol 2005;5:365–369.
38.
Schuster-Boeckler B, Schultz J, Rahmann S: HMM logos for visualization of protein families. BMC Bioinformatics 2004,5:7–12.
39.
Valenta R, Hayek B, Seiberler S, Bugajska-Schretter A, Niederberger V, Twardosz A, et al: Calcium-binding allergens: from plants to man. Int Arch Allergy Immunol 1998;117:160–166.
40.
Twardosz A, Hayek B, Seiberler S, Vangelista L, Elfman L, Gronlund H, Kraft D, Valenta R: Molecular characterization, expression in Escherichia coli, and epitope analysis of a two EF-hand calcium-binding birch pollen allergen, Bet v 4. Biochem Biophys Res Commun 1997;239:197–204.
41.
Suphioglu C, Ferreira F, Knox RB: Molecular cloning and immunological characterisation of Cyn d 7, a novel calcium-binding allergen from Bermuda grass pollen. FEBS Lett 1997;402:167–172.
42.
Zhang S, Li B, Weil GJ: Human antibody responses to Brugia malayi antigens in brugian filariasis. Int J Parasitol 1999;29:429–436.
43.
Radauer C, Breiteneder H: Pollen allergens are restricted to few protein families and show distinct patterns of species distribution. J Allergy Clin Immunol 2006;117:141–147.
44.
Ramalingam TR, Reiman RM, Wynn TA: Exploiting worm and allergy models to understand Th2 cytokine biology. Curr Opin Allergy Clin Immunol 2005;5:392–398.
45.
Waine GJ, Mazzer DR, McManus DP: Production of IgE antibodies against the 22-kDa tegumental membrane-associated antigen of schistosomes is directed by the antigen itself. Parasite Immunol 1997;19:531–533.
46.
Naus CW, Booth M, Jones FM, Kemijumbi J, Vennervald BJ, Kariuki CH, Ouma JH, Kabatereine NB, Dunne DW: The relationship between age, sex, egg-count and specific antibody responses against Schistosoma mansoni antigens in a Ugandan fishing community. Trop Med Int Health 2003;8:561–568.
47.
Blumenthal M. Namboodiri NK, Mendell N, Gleich G, Elston C, Yunis E: Genetic transmission of serum IgE Levels. Am J Med Genet 1981;10:219–228.
48.
Booth M, Shaw MA, Carpenter D, Joseph S, Kabatereine NB, Mwatha JK, Jones FM, Macbeath R, Ouma JH, Dunne DW: Carriage of DRB1*13 is associated with increased post-treatment IgE levels against Schistosoma mansoni antigens, and lower long-term re-infection levels. J Immunol 2006;176:7112–7118.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.